PT-141 (Bremelanotide) for Female Sexual Dysfunction: Risks, Benefits, and What the Evidence Actually Shows

What Is Bremelanotide and Why Are Women Asking About It?

Bremelanotide is a synthetic melanocortin receptor agonist that acts centrally, meaning it works in the brain rather than on the genitals or blood vessels. It was developed from a naturally occurring peptide called alpha-melanocyte-stimulating hormone and acts primarily on MC3R and MC4R receptors in areas of the brain involved in sexual motivation and arousal. The FDA approved it in August 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

HSDD is the most common female sexual dysfunction diagnosis in the United States, affecting an estimated 10% of adult women at any given time, though prevalence rises sharply around perimenopause.

The "PT-141" name comes from its peptide research designation. That label persists in compounding pharmacy catalogs and online forums, which is one reason women encounter it as a wellness or off-label option well beyond its approved indication.

How It Differs from Flibanserin

Flibanserin (Addyi) is the other FDA-approved drug for HSDD in premenopausal women. It is a daily oral serotonin modulator. Bremelanotide is on-demand, injected subcutaneously with an autoinjector pen no more than once per 24-hour period and no more than once per day. Women who cannot tolerate a daily pill, or who want situational rather than continuous therapy, often prefer bremelanotide.

The Off-Label Field

Because the FDA approval is narrow (premenopausal women, HSDD only), any use in perimenopausal women, postmenopausal women, or for arousal disorder, orgasmic disorder, or sexual dysfunction caused by antidepressants is considered off-label. Prescribing a drug off-label is legal and common in medicine, but it means the evidence base is thinner and the risk-benefit calculation is less defined.

The Approved Indication: HSDD in Premenopausal Women

What the Key Trials Found

The FDA approval was based on two double-blind, randomized, placebo-controlled trials, RECONNECT Study 1 and Study 2, both published in Obstetrics & Gynecology in 2019. Combined, the trials enrolled 1,267 premenopausal women with HSDD.

The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13. Women using bremelanotide showed a statistically significant improvement on both endpoints compared with placebo at 24 weeks. Mean desire scores improved by approximately 0.3 points on the FSFI desire subscale over placebo, a modest but clinically meaningful difference for women who had tried nothing else.

Roughly 25% of treated women reported being "much improved" or "very much improved" on global impression scales, compared with 17% on placebo.

What GRADE Says About This Evidence

The trials were well-designed, but the effect sizes are modest. Most methodologists would rate this evidence as GRADE moderate: adequately powered RCTs with consistent direction of effect, but meaningful questions remain about long-term benefit, optimal patient selection, and whether subjective desire scores translate to women's lived satisfaction.

Off-Label Use: Who Is Actually Asking for PT-141?

Perimenopausal Women

Perimenopause, the years of hormonal fluctuation before the final menstrual period, is associated with a steep decline in sexual desire for many women. Estradiol variability, rising FSH, and declining testosterone all converge. The RECONNECT trials excluded women who were perimenopausal or postmenopausal, so there is no randomized controlled trial evidence for bremelanotide in this group.

Clinicians who prescribe it off-label in perimenopausal women often reason that the central melanocortin mechanism is not estrogen-dependent, meaning the brain circuitry it targets does not require high estrogen to respond. That is pharmacologically plausible but not confirmed in this population.

Postmenopausal Women

The evidence gap is largest here. No published phase 3 trial has enrolled postmenopausal women. Small observational and case-series data exist, but they do not meet the bar for a treatment recommendation. The Menopause Society's 2022 position statement on sexual health does not endorse bremelanotide for postmenopausal women, noting that genitourinary syndrome of menopause (GSM) and androgen insufficiency are separate contributors that bremelanotide does not address.

For postmenopausal women with low desire, clinicians typically prioritize local vaginal estrogen for GSM, systemic hormone therapy if indicated, and testosterone therapy (itself off-label for women in the United States) before considering bremelanotide.

Women with PCOS

PCOS is the most common endocrine disorder in reproductive-age women, affecting 8-13% of this group worldwide. Sexual dysfunction, including low desire and arousal problems, is more prevalent in women with PCOS than in age-matched controls, possibly due to androgen excess paradoxically suppressing central desire pathways, body image concerns, and mood comorbidities. There are no published RCTs of bremelanotide specifically in women with PCOS. Its use here is extrapolated from the general HSDD approval and is considered off-label.

Antidepressant-Induced Sexual Dysfunction

SSRIs and SNRIs are among the most common causes of acquired sexual dysfunction in women of reproductive age. A 2016 systematic review in CNS Drugs estimated that up to 80% of people on SSRIs report some degree of sexual side effect. Bremelanotide's mechanism, working through melanocortin rather than serotonin or dopamine directly, has generated interest as a possible counteragent. A small proof-of-concept study published in Psychopharmacology in 2017 showed preliminary signal for bremelanotide improving desire in women on antidepressants, but the sample size was too small (N=24) to guide clinical practice. This use remains speculative at GRADE very low evidence.

Compounded PT-141: A Specific Warning

A substantial portion of women accessing PT-141 online are receiving compounded bremelanotide from non-FDA-registered pharmacies, not the branded Vyleesi autoinjector. The FDA has warned repeatedly about compounded peptides including bremelanotide, citing concerns about potency, sterility, and the absence of the proprietary formulation data that underpinned the approval.

Compounded PT-141 is frequently sold in lyophilized (freeze-dried) powder vials requiring reconstitution with bacteriostatic water, and doses vary widely. The approved Vyleesi dose is 1.75 mg. Online sources may sell vials ranging from 5 mg to 10 mg with instructions that have no clinical basis. Women using compounded PT-141 from unregulated sources are taking on additional, unquantified risks beyond those established in trials.

A practical framework for evaluating any bremelanotide source: Is it dispensed by a licensed U.S. Pharmacy? Does it require a valid prescription from a licensed prescriber? Is the form the 1.75 mg autoinjector or a documented compounding pharmacy product from an FDA-registered 503B outsourcing facility? If the answer to any of these is no, the safety profile is unknown.

Side Effects, Risks, and Who Should Not Use It

Common Side Effects

In the RECONNECT trials, the most frequently reported adverse effects were:

• Nausea: approximately 40% of women (most within one hour of dosing, usually resolving within 12 hours)
• Flushing: approximately 20%
• Injection-site reactions: approximately 13%
• Headache: approximately 11%
• Transient blood pressure increase: mean systolic increase of approximately 2 mmHg, mean diastolic increase of approximately 1 mmHg in trials, but with individual spikes up to 6 mmHg systolic in some women

Nausea is the primary reason women discontinue the drug. Taking it 45 minutes before anticipated activity on a light stomach worsens nausea; taking it after a light meal may help, though this is not formally studied.

Cardiovascular Considerations

Bremelanotide causes a transient, dose-dependent increase in blood pressure that begins within one hour and resolves within 12 hours. It is contraindicated in women with uncontrolled hypertension or known cardiovascular disease. Women with well-controlled hypertension on stable therapy were not systematically studied, and prescribers typically use clinical judgment in borderline cases.

Hyperpigmentation

With repeated use, bremelanotide can cause focal hyperpigmentation of the face, gums, and breasts due to its melanocortin receptor activity. This appears to be more common with frequent dosing. Women with darker Fitzpatrick skin types may be at greater risk of noticeable change, though this has not been systematically studied by skin type. The label recommends not using bremelanotide more than once per 24 hours.

Drug Interactions

Bremelanotide can slow gastric emptying and reduce the rate of oral drug absorption. Specifically, it delays the absorption of naltrexone, which is clinically relevant because some women on combined bupropion/naltrexone (Contrave) for weight management may be prescribed both.

Pregnancy, Lactation, and Contraception

Bremelanotide is contraindicated in pregnancy. This is not a precautionary soft warning. Animal reproductive studies showed embryofetal toxicity at doses below the human therapeutic dose, and there are no adequate human data. The FDA label states that women who become pregnant during treatment should stop immediately and that exposure during early pregnancy should prompt discussion with an obstetric provider.

The FDA recommends discontinuing bremelanotide at least one menstrual cycle before attempting to conceive. Women of reproductive age who are not using reliable contraception should not be prescribed this drug.

Lactation: There are no human data on the transfer of bremelanotide into breast milk. Because the drug is a peptide, it may undergo some degradation in the infant's gut, but the potential for central nervous system effects via any absorbed fraction is unknown. Given the lack of data and the drug's central mechanism, most clinicians advise against use during breastfeeding. The LactMed database does not list bremelanotide as compatible with lactation.

Contraception requirements: Any woman of reproductive age receiving bremelanotide should be using reliable contraception. This is not about drug interactions with hormonal contraceptives, as no significant pharmacokinetic interaction has been documented. It is about the teratogenic signal in animal data and the absence of human pregnancy safety data.

For women trying to conceive who also have HSDD: bremelanotide is not an appropriate therapy during a conception attempt. Addressing low desire in a fertility context may require psychological support, relationship therapy, and treatment of any underlying hormonal contributors, rather than a drug contraindicated in early pregnancy.

Who This Is Right For (and Who It Is Not Right For)

Life Stage Matching

Reproductive-age women with HSDD, not trying to conceive: This is the approved population. Bremelanotide is a reasonable second-line option after ruling out treatable underlying causes (thyroid disease, depression, relationship factors, medication side effects) and after a shared-decision conversation about the modest effect size and nausea burden.

Perimenopausal women with HSDD: Off-label but pharmacologically defensible. The clinician must confirm that GSM symptoms are addressed (usually with local estrogen), that depression and sleep disruption from perimenopause are managed, and that testosterone deficiency is considered. Bremelanotide does not replace estrogen or testosterone.

Postmenopausal women: Off-label with very limited evidence. The Menopause Society recommends addressing GSM, systemic hormone therapy where appropriate, and ospemifene or local estrogen as first priorities. Bremelanotide may be added in discussion with a menopause-specialist provider, but it should not be first-line.

Women with PCOS and low desire: Off-label, reasonable to consider after addressing hyperandrogenism, mood, and metabolic factors inherent to PCOS. No PCOS-specific dosing guidance exists.

Women on SSRIs with sexual dysfunction: Speculative, GRADE very low evidence. First-line strategies include dose reduction, drug holiday, switching to bupropion or mirtazapine, or adding bupropion. Bremelanotide is not a standard adjunct in this setting.

Who Should Not Use It

• Women who are pregnant or planning pregnancy in the next menstrual cycle
• Women currently breastfeeding
• Women with uncontrolled hypertension or known cardiovascular disease
• Women with a history of hyperpigmentation disorders who are concerned about facial or gingival pigment changes
• Women who require reliable oral drug absorption within four hours of dosing (e.g., time-sensitive narrow-therapeutic-index medications taken at night)
• Women obtaining it from unregulated online sources without a licensed prescriber

The Honest Evidence Gap: What We Do Not Know

Women have been systematically underrepresented in sexual medicine research for decades, and bremelanotide research is no exception in one particular respect: the approved trials did not include perimenopausal or postmenopausal women, women with concurrent hormonal disorders, or women from diverse racial and ethnic backgrounds in proportions that allow meaningful subgroup analysis.

As Simon et al. Noted in Obstetrics & Gynecology (2019), the RECONNECT population was predominantly white (approximately 79%) and the mean age was 38 years, limiting generalizability to women across the full life span or across racial groups with potentially different baseline desire trajectories.

We do not have good data on:

• Long-term efficacy beyond 24 weeks
• Optimal dosing frequency to minimize hyperpigmentation while maintaining benefit
• Whether response varies by hormonal contraceptive type (combined oral contraceptive vs. Progesterone-only vs. Hormonal IUD)
• Safety in women with well-controlled autoimmune conditions or on immunomodulatory therapy

Extrapolating freely from the premenopausal HSDD trial to all women with sexual dysfunction is scientifically unjustified. Honest prescribing in this space means naming that gap to the patient.

How Bremelanotide Fits With Other Female Sexual Dysfunction Treatments

Putting It in a Treatment Sequence

A 2020 clinical practice update in Obstetrics & Gynecology by Kingsberg and colleagues described a stepped approach to female sexual dysfunction:

1. Identify and treat organic causes first (thyroid disease, prolactinoma, medication side effects, GSM, depression, pelvic floor dysfunction).
2. Address psychological and relational contributors with sex therapy or cognitive-behavioral therapy.
3. Consider hormonal therapies where appropriate (testosterone for androgen insufficiency, estrogen for GSM).
4. Use pharmacotherapy for desire disorders when steps 1-3 are insufficient.

Bremelanotide sits at step 4, and even there it competes with flibanserin (Addyi) and, in postmenopausal women, testosterone. Choosing between them depends on patient preference (daily pill vs. On-demand injection), tolerance of nausea, cardiovascular history, and whether the primary complaint is desire versus arousal versus orgasm.

What It Does Not Treat

Bremelanotide has no demonstrated effect on genital arousal disorder in the absence of desire problems, on orgasmic disorder as a primary complaint, on dyspareunia, or on vaginismus. Women whose primary concern is pain with intercourse should be evaluated for GSM, vestibulodynia, vulvodynia, or pelvic floor hypertonicity, none of which bremelanotide addresses.